Celgene Corp (CELG)
Healthcare | Biotechnology
CEO: Mark J. Alles
Celgene Corp receives a in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Celgene Corp's valuation score is comprised of a P/E ratio of 44.3x, a P/B ratio of 12.4x, a P/S ratio of 8.1x, and an EV/EBITDA ratio of 29.2x. .
WARREN BUFFETT RANKING
Celgene Corp ranks 343 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Celgene Corp appears to have a durable competitive advantage within the Healthcare sector.
Celgene Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 5.83x, a debt/equity ratio of 187% and a Moat Rank of 42 translate to a strong Financial Strength score.
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 18.36% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 169.
VALUE + YIELD
Celgene Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology.
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. Its 11.8% 5 year annualized EPS growth, 17.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 6.1% speak to its impressive growth ranking.